Articles On Imugene (ASX:IMU)

Highlights The ASX 200 closed 0.3% higher with energy stocks rising on a 7-year high for oil of $US96 per barrel. Asian stock markets fell, and oil prices rose amid concern about a possible Russian invasion of Ukraine. The global cryp...

Local shares moved higher today. Investors took to safety, betting on gold producers on concerns that Russia may invade Ukraine this week. Aussie gold stocks buoyed the ASX 200, which closed 0.28% higher, defying Wall Street as well as othe...

Aussie shares overcame weak leads and early pressure to start the week higher as geopolitical concerns stoked a “gold rush” in mining stocks. The S&P/ASX 200 finished with a gain of 27 points or 0.37 per cent. A see-saw session saw t...

Australian stocks edged higher following a volatile morning as investors weighed geopolitical tensions and inflation and rates worries. An up-tick in US equity futures helped the S&P/ASX 200 overcome weak leads. The Australian benchm...

On 9 February 2022, the equity market of Australia settled in green. On the same day, ASX Midcap50 was up by 1.42% and ASX 200 moved up by 1.13%. ASX All Ordinaries rose by 1.12% to 7,572.60. Data Source: ASX, Table Source: Copyright © 2...

Highlights Australian shares advanced 0.98% to 7,257, boosted by a strong session for the financial and technology sectors. Wall Street's positive end lifted the spirits across Asian stock markets. Major cryptocurrencies by market val...

Today, the S&P/ASX 200 Index (ASX: XJO) climbed further out of its recent January dip. At the end of the session, the benchmark index finished 1.14% higher at 7,268.3 points. Only two sectors left investors in the red on the ASX today...

Imugene company director Dr Jens Eckstein acquired 15 million shares, displaying his confidence in the company. Imugene's share price closed at $0.32 as investors piled in after the change of director's interest notice was published to the...

Aussie shares climbed 1.13% higher today, boosted by a tech stock rally. The XIJ tech index rose by more than 4%, buoyed by Nasdaq’s 1% rise overnight and strong earnings results from local stocks. The Financial sector was the other big win...

V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts, listed small caps and industry players. This latest video conference focuses on Tim Bor...

“Commercial success outside these financially modelled programs would serve as potential upside to our valuation,” the broking firm said in its report.  

Highlights The ASX 200 rallied toward the close, paring back losses that stood as much as 0.5% before rising through the noon to end the day 0.1% lower. Shares in Asian markets were mixed amid persisting concerns about global growth an...

The ASX 200 got off a slow start but held its ground throughout Thursday trade, to finish 0.14% lower at the close. Large cap miners held the fort, offsetting another brutal session for tech stocks which are increasingly subject to volatile...

A Facebook-fuelled collapse in US futures triggered heavy selling in Australian tech stocks, pulling the ASX 200 from a one-week high. The Australian benchmark ended 10 points or 0.14 per cent lower as strength in mining and utility stoc...

Aussie shares retreated from a one-week high after downbeat earnings from Facebook and Paypal triggered heavy selling in tech stocks. The S&P/ASX 200 sank 25 points or 0.35 per cent. The decline dented a rally that had lifted the ben...

On 01st February 2022, the equity market of Australia closed in green. On the same day, ASX Midcap50 was up by 1.03% and ASX 200 moved up by 0.49%. ASX All Ordinaries rose by 0.61% to 7,312.80. Data Source: ASX, Table Source: Copyright ©...

Today, the S&P/ASX 200 Index (ASX: XJO) rallied off the back of a strong showing on Wall Street last night. On top of this, the Reserve Bank of Australia decided to keep interest rates on hold. At the end of the session, the benchmark...

ASX large caps posted steady gains in Tuesday trade, as tech stocks and financials gained while resources stocks lagged behind. It marked a reversal of the broader January trend, as money pour into the mining sector while large cap tech sto...

Dr Cha will lead the company’s global clinical development efforts and medical affairs at a pivotal time of its growth. 

The share market retreated ahead of a week of risk events including a Reserve Bank policy meeting and monthly US jobs data.   The S&P/ASX 200 eased 20 points or 0.28 per cent as investors waited to see if Friday’s rebound on global e...

Immuno-oncology company Imugene (IMU) is granted a Japanese patent which protects its cancer-treating oncolytic virotherapy to 2037 The notice of grant received from the Japanese Patent Office protects the method of composition and method...

“Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese patent office is a crucial step forward and is the first of many expected patent grants from multiple countries," says CEO.

On 28th January 2022, the stock market in Australia ended in green. On the same day, ASX 20 rose by 2.45% and ASX MIDCAP50 has witnessed a rise of 1.82%. Also, ASX 100 rose by 2.12% as well as ASX 200 has encountered a rise of 2.19%. Dat...

Today, the S&P/ASX 200 Index (ASX: XJO) fought back against the selling pressure throughout the day to finish in the green. At the end of trade, the benchmark index was 2.19% higher at 6,988.1 points. In stark contrast to the rest of...

We’ve all gone a little bit crackers on Friday – or as the Kiwi’s like to say in French – un peu fou de fafa. Trading volumes – unless I’m drunk – are about double what they usually are. Wait… 95% above the 20-day moving average. It’s a lot...

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined with an immune checkpoint inhibitor The deal is expected to last up to five years The Imugene Limited (ASX: IMU) sha...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is rebounding strongly from recent declines. At the time of writing, the benchmark index is up 2.3% to 6,994.7 points. Four ASX shares that are climbing more than most today are list...

28 Jan 2022 - Bio-tech company Imugene (ASX:IMU) has made two announcements today regarding its HER-Vaxx and PD1-Vaxx.

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for the company’s HER-Vaxx immunotherapy Today’s news follows recent South Korean patent award Imugene Limited (ASX...

Clinical stage immuno-oncology company Imugene (IMU) granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer The patent entitled “A Vaccine Composition and Uses Thereof” protects the method of...

The patent protects the company's gastric cancer treatment, HER-Vaxx, for method of composition and method of use in the important European market until 2036. 

ASX is up in a wild session that has seen big swings. Ramelius tumbles as WA's closed border hits guidance, Newcrest falls on production update and Imugene rallies.

Highlights Australian shares fell 0.5%, or 36.3 points to 7139.5 today. Investing sentiment today was weighed down by losses across the materials and technology sectors. Investors await an array of economic updates and meetings this w...

Fears of a market meltdown subsided early today as the ASX 200 fell by just 0.5%, lifted by the bounce back in US stock futures in Asian trading. A rush of US earnings reports in the next few days, along with the two-day Federal Reserve mee...

Highlights Today, the ASX 200 closed sharply lower; the broad-based decline was led by the materials and energy sectors. Asian share markets and US futures also fell. The global crypto market cap tanked more than 5%. Today, the AS...

ASX health stocks (XHJ index) are down .99% today but faring better than the ASX 200 which has fallen sharply at 1.5%. The HeraMED (ASX:HMD) share price rallied 6.9% to 31 cents in early morning trade before settling ~3.45% as the company a...

The company thanked Dr Laeufle for her role in advancing Imugene's clinical activities - it is now in the final stages of recruiting a new immuno-oncology expert to assume the role of chief medical officer.

Highlights The ASX 200 closed 1% lower today, thanks to a sell-off in US stocks overnight. Investors withdrew from risk assets; government bond yields scaled up. Asian stocks also traded in the red zone. The global cryptocurrency mar...

A risk-off down-shift on global markets pushed Australian shares to their weakest close of the year as spikes in energy prices and lending rates added to investor worries. The S&P/ASX 200 sank 76 points or 1.03 per cent to 7333. The...

On 18th January 2022, the equity market of Australia closed in red. On the same day, ASX Midcap50 rose by 0.04% and ASX 200 was down by 0.11%. ASX All Ordinaries moved down by 0.05% to 7,735.80. On the same day, ASX 100 also encountered a f...

Today, the S&P/ASX 200 Index (ASX: XJO) slipped to the downside after starting off in the green. At the end of the session, the benchmark index finished 0.11% lower at 7,408.8 points. Investors were split on how to view the Aussie sha...

Local markets were somewhat directionless today as Wall Street took time out for the Martin Luther King Jr holiday overnight. The ASX 200 failed to maintain early momentum, finishing the day in the red down by 0.11%. The Mining index was hi...

Highlights The ASX 200 added 48.8 points and closed at 7438.9 today, thanks to a strong session by energy and technology stocks. Asian stocks witnessed a rebound, same as their American peers after Jerome Powell reassured investors the...

Today, the S&P/ASX 200 Index (ASX: XJO) pulled higher in a similar fashion to Wall Street’s showing last night. At the end of the session, the benchmark index finished 0.66% higher at 7,438.9 points. Pleasingly, most of the sectors ac...

The ASX 200 was up 0.59% today after a flat start to the week. Both US and EU stocks rose after US Federal Reserve Chairman Jerome Powell reiterated the central banks efforts to corral inflation before the Senate Banking Committee. Powell s...

The money will support the immuno-oncology company’s commercial and clinical milestones, several of which it has ticked off in the last few weeks.

Highlights  The ASX 200 fell 2.7%, following a sharp drop for US stocks overnight after Federal Reserve meeting minutes suggested a quicker run of rate increases. Investors are also nervous about the sharp spike in Omicron cases. Cryp...

The ASX 200 plummeted ~2.7% today, with a huge 6% selloff in the Tech sector weighing heavily on the index. All eleven sectors were in the red, following falls in Wall Street overnight that saw tech heavy Nasdaq slipping by 3.3%. Recent inv...

The Imugene Limited (ASX: IMU) share price is sliding in negative territory today despite a positive company update. At the time of writing, the immuno-oncology company’s shares are down 7.18% trading at 36 cents. It’s worth noting that Im...